Jos Morales, MD, a vascular neurologist and neurointerventional surgeon at Providence Saint Johns Health Center in Santa Monica, CA, also not involved in this review, told MNT that microglias effect on the neurovascular unit has been associated with dementia. He suggested that: [GLP-1 drugs] could potentially modulate inflammation to reduce the propensity for developing dementias such as Alzheimers disease, particularly in the setting of metabolic syndrome. Morales also explained that in people who have glycemia or type 2 diabetes, the inflammation of the blood-brain barrier can lead to progressive damage to the brain over longer periods. He noted that trials that combine neuroimaging techniques that measure the blood-brain barrier and GLP-1 treatment are needed and could prove that these drugs have neuroprotective benefits.

Specifically, the FDA considered claims that compounded products are generic versions or contain the same active ingredient as FDA-approved GLP-1 drugs are false or misleading
Those are the questions TRIUMPH-2 and TRIUMPH-3 are designed to answer later in 2026
In Mississippi, semaglutide injections can be given by professionals with the titles MD, DO, NP, PA, RN, or LPN